ImmunoGen Stock News

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Related Stocks: ASLN , ANIP , ALLK , IMGN , BLU , LEGN , BCAB , APVO , NXTC ,

ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

ImmunoGen Inc (NASDAQ: IMGN ) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY ) to grant exclusive rights to research, develop, and commercialize antibody-drug conjugates (ADCs) directed to targets selected by Lilly based on ImmunoGen''s camptothecin technology. Camptothecins are an important class of anticancer drugs targeting Type I topoisomerase. According to the deal, Lilly … Full story available on Benzinga.com

ImmunoGen Inc. shares jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Camptothecins are a class of cancer drugs. Under the terms of the deal, ImmunoGen will receive $13 million upfront and up to $32.5 million for meeting certain targets. "ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones," the company said in a statement. It will also be eligible for certain tiered royalties as a percentage of worldwide sales. ImmunoGen shares have fallen 47% in the last 12 months, while the S&P 500 has gained 12%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion

ImmunoGen Inc. shares IMGN, -3.82% jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. LLY, -0.03% of its Novel Camptothecin ADC Platform for up

The graphene specialist said orders had come from and been 'ImmunoGen' (NASDAQ:IMGN) universities alongside strong Middle East interest, online inquiries, and from B2B customers.Large distribution dea

ImmunoGen Inc. (NASDAQ:IMGN) price closed higher on Monday, February 07, jumping 3.95% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Phase 1 data for its ovarian cancer candidate was a little disappointing.